Red light therapy
and wound healing
Wound healing is where the evidence base for red light therapy started - and where it remains most robust. From chronic diabetic ulcers to post-surgical scars, here is what six decades of clinical research actually shows.
Where it all started
In 1967, a Hungarian physician named Endre Mester set out to test whether laser light could cause cancer in mice. It did not. But the mice exposed to low-level red laser light healed faster than those that were not - and grew their shaved hair back more quickly. That serendipitous finding was first published the same year in Hungarian, with the wound healing work in humans following from 1971 onwards. It became the founding observation of photobiomodulation. Wound healing has been its most studied application ever since.
The NovaThera skin conditions blog covers wound healing and scarring as part of a broader six-condition overview. This blog goes deeper: the four-phase biology, the specific clinical trial parameters, what the diabetic wound data actually shows, and a practical timing guide for different wound types. If you found this page from there, this is the detail behind those summaries.
Wound healing is the application where red light therapy has the longest track record, the strongest mechanistic understanding, and the largest gap between what is known clinically and what most people who own a panel are aware of.
Why light speeds up healing
Wound healing is a four-phase biological process. Red and near-infrared light do not skip any of these phases - they support each one by improving the cellular environment in which the process happens.
The four phases of wound healing - and where PBM acts
Bleeding stops, a clot forms. PBM has minimal direct effect here - this phase is fast and largely mechanical. The benefit begins in the phase that follows.
Immune cells clear debris and bacteria. PBM reduces excessive inflammatory signalling without suppressing the immune response itself - calming the environment so repair can begin.
Fibroblasts produce collagen, new blood vessels form, and the wound closes. PBM directly stimulates fibroblast activity and angiogenesis - this is where the acceleration happens.
Collagen reorganises, scar tissue matures. PBM supports more organised collagen deposition and reduces the overproduction that leads to raised or thickened scars.
The three cellular mechanisms driving these effects are well-established in the literature. Mitochondrial stimulation increases ATP production, giving cells the energy needed for repair. Nitric oxide release improves local blood flow, delivering oxygen and nutrients to the wound site. And modulation of inflammatory cytokines - particularly a reduction in TNF-alpha and interleukin-1 - creates a more controlled healing environment rather than a prolonged inflammatory state that impairs recovery.
In diabetic wounds and other compromised healing situations, these mechanisms are particularly relevant. Diabetes impairs mitochondrial function, reduces local circulation, and sustains chronic inflammation - exactly the three problems PBM addresses most directly.
Where the evidence sits across the four main wound-healing applications - from the most established down.
Chronic wounds - diabetic ulcers and pressure ulcers
28 RCTs confirm benefit for diabetic foot ulcers. Incorporated in wound care protocols in multiple countries. 2024 JAAD expert consensus panel endorses PBM for ulcers.
Post-surgical wound healing
Multiple RCTs on incision healing after surgery. International consensus guidelines recommend early laser use post-operatively for wound optimisation and scar mitigation.
Hypertrophic scar prevention
RCT evidence shows early 830nm LED application after surgery significantly reduces hypertrophic scar formation. Prevention is stronger than treatment of established scars.
Everyday wounds - cuts, burns, abrasions
Mechanistic case is strong and consistent with other applications. Direct home-use RCT evidence is thinner, but the biology is the same as in clinical settings.
Diabetic foot ulcers are one of the most difficult wound problems in medicine. They affect between 19% and 34% of people with diabetes over their lifetime - a figure that is rising as life expectancy increases - are prone to infection, and are the leading cause of non-traumatic limb amputation. The standard of care - offloading, debridement, dressings, antibiotics - produces complete healing in only around half of cases. The rest become chronic wounds that persist for months or years.
PBM has been investigated as an adjunct in this setting more thoroughly than almost any other wound type. A 2024 meta-analysis reviewed 28 randomised controlled trials of red and infrared light for diabetic foot ulcers and confirmed PBM significantly reduces ulcer area compared to standard care - with one RCT of Wagner grade 1-2 ulcers showing 51% relative ulcer size reduction at 8 weeks versus 24.5% in controls. A separate RCT by Torkaman et al. using 904nm Ga-As laser PBM in 30 diabetic patients with grade II foot ulcers found accelerated wound closure (p=0.003) and normalised angiogenic markers, with VEGF levels reducing (p=0.005) and nitric oxide increasing (p<0.001) in treated tissue.
The mechanism in diabetic wounds is exceptionally direct. Diabetes impairs all three of PBM's primary targets simultaneously: mitochondrial function is compromised by hyperglycaemia and advanced glycation end products; nitric oxide bioavailability is reduced by oxidative stress, impairing the vasodilation needed to perfuse healing tissue; and the inflammatory environment is chronically dysregulated, preventing the normal transition from inflammatory to proliferative phase. PBM addresses each of these independently. This is not a case of applying a general treatment to a specific disease - the mechanism maps precisely onto the failure modes of diabetic wound healing.
Clinical protocols in the published RCTs typically use wavelengths of 630-660nm (red) or 810-904nm (NIR), irradiance of 20-100 mW/cm², energy densities of 2-10 J/cm², and treatment sessions of 5-20 minutes applied directly to the wound surface or through an appropriate dressing. Most studies used 3-5 sessions per week over 4-12 weeks. These parameters give a useful anchor for anyone supporting medical wound care with a home panel - the key variables are consistent coverage of the wound site, adequate energy delivery per session, and frequency of at least three times weekly.
Important framing on chronic wounds
For diabetic foot ulcers and pressure ulcers, PBM is an adjunct to medical wound care - not a replacement for it. Debridement, infection management, offloading, and glucose control remain the foundation. What the evidence supports is that adding PBM to standard care improves healing outcomes. If you or someone you care for has a chronic wound, this is a conversation for a wound care specialist, not something to manage at home alone.
Post-surgical wound healing is one of the clearest home panel applications in this whole area. The reason is simple: surgery is performed on otherwise healthy tissue, with controlled incisions, in a sterile environment. The wound healing that follows is not complicated by diabetes, vascular disease, or infection in most cases - it is a clean biological process that PBM can support directly.
A 2020 systematic review by Artzi et al. looked at 14 clinical studies of laser treatment for post-operative wounds, covering surgery sites including breast, thyroid, hernia, and plastic surgery procedures. The recommendation from that review: early post-operative application - from the point of suture removal - using diode lasers produces the best outcomes for wound appearance, pliability, and tissue quality. Published in Plastic and Reconstructive Surgery Global Open (PMID 32440416). An international consensus guideline on post-surgical and traumatic scarring states directly that laser therapy improves wound appearance, pliability, and range of motion, and should be considered a primary therapeutic option for scar mitigation.
A randomised, double-blind, sham-controlled RCT of 43 patients using 830nm LED-based PBM after thyroidectomy (a surgery with higher-than-average hypertrophic scar risk) found significantly better scar scores on the Vancouver Scar Scale and lower pain scores at six months compared to controls. Improvements were seen in colour, height, pigmentation, and vascularity. The conclusion: early 830nm LED application significantly prevents hypertrophic scar formation and reduces post-operative pain without adverse effects. PMID 36045183.
Timing is everything for surgical wounds
The evidence consistently points to early application as the key factor. Starting PBM in the first days after suture removal - when the proliferation phase is active and collagen deposition is underway - produces better outcomes than later use on established scars. The window matters. If you have had surgery and want to use a panel to support healing and reduce scarring, the time to start is in the first weeks of recovery, not months later when the scar has already set.
Which leads directly to the question most people actually want answered: what can red light therapy do about a scar that has already formed?
Three scar types - and where PBM is most effective
Normal scar
Flat, fading, within wound margins. The expected outcome of well-healed tissue. Pale and softening by 6-12 months.
Hypertrophic scar
Raised, red, firm. Stays within wound boundaries. Caused by excess collagen during proliferation. Can improve over time.
Keloid
Grows beyond wound edges. Driven by dysregulated fibroblasts. Does not resolve without intervention. More common in darker skin tones.
Scars are not all the same. A fine, flat scar is the normal result of wound remodelling. A hypertrophic scar is raised, red, and forms within the original wound boundaries - usually from excessive collagen production during the proliferation phase. A keloid goes further: it grows beyond the wound edges, driven by continued fibroblast activity, and does not resolve on its own.
The mechanism by which PBM influences scar formation is better characterised than most applications. The key pathway involves matrix metalloproteinases (MMPs) - enzymes that break down and rebuild the extracellular matrix - and their regulator TGF-beta. In normal wound healing, TGF-beta signalling drives collagen deposition. In hypertrophic scars and keloids, TGF-beta activity is chronically elevated, producing the disorganised, excessive collagen that gives raised scars their texture and firmness. Red light at 630-660nm has been shown in fibroblast studies to modulate TGF-beta pathway activity and MMP expression, shifting the remodelling balance away from fibrotic overproduction toward more organised matrix architecture.
The most rigorous clinical evidence comes from the CURES trial (Cutaneous Understanding of Red-light Efficacy on Scarring), a randomised, mock-controlled, split-face phase II trial funded by the NIH (K23GM117309), published in the Journal of Biophotonics (Kurtti et al. 2021, PMID 33788987). Starting one week after surgery, red LED light was applied to incision sites at three different fluences - the opposite side of the face received mock therapy as a control. At six months, medium-dose treated scars showed a 77.8% decrease in induration (firmness) compared to 50% in the untreated controls. The split-face design is critical: by comparing treated and untreated scars within the same patient, it eliminates the individual variation in healing that confounds between-group comparisons.
The CURES trial used 630nm LED at 90 J/cm² for the medium dose, applied starting at day 7 post-surgery, three times weekly. That protocol detail matters for anyone using a panel post-operatively - the timing (early, not late) and consistency (three times weekly minimum) are both supported by the trial data. The in vitro work from the same SUNY Downstate research group extends this: red LED inhibits keloid fibroblast proliferation and reduces TGF-beta1-stimulated collagen synthesis in human skin fibroblasts in a dose-dependent manner. The 2025 JAAD expert consensus panel listed scar management as one of PBM's established clinical applications.
What PBM can and cannot do for scars
PBM can support more organised healing and help prevent excessive scar formation when used early. It can gradually improve the texture, colour, and softness of established hypertrophic scars with consistent use. It cannot dissolve an existing scar, reverse structural changes that have already set, or reliably resolve a keloid on its own. The earlier you start, the more there is to work with biologically. An old, flat, pale scar has largely finished remodelling and will show minimal response.
Most people do not have diabetic foot ulcers or scheduled surgery. What they have is the ongoing accumulation of everyday wounds - cuts from cooking, abrasions from sport, minor burns, blisters, skin splits in winter. The clinical evidence does not directly study these in home settings with LED panels. But the biology is identical to what the clinical trials are measuring.
Fibroblasts in a cut finger respond to red and NIR light through the same cytochrome c oxidase pathway as fibroblasts in a diabetic ulcer. The inflammatory cytokines that slow healing in a minor abrasion are the same ones PBM modulates in post-surgical tissue. The collagen deposition that determines whether a cut leaves a flat scar or a raised one follows the same four-phase process. What the clinical evidence establishes is that PBM accelerates and improves this process. There is no biological reason that stops at a certain wound severity threshold.
The practical implication: for everyday cuts and abrasions, starting a session within the first 24-48 hours - when the wound is in the inflammatory phase and transitioning into proliferation - gives PBM the most to work with. Clean the wound normally first. Do not apply the panel to an open, unhealed wound with active bleeding. Once closed or scabbed over, the tissue is accessible to light and the healing support can begin.
Dermatologists increasingly combine red and NIR LED therapy with ablative and non-ablative skin procedures - laser resurfacing, microneedling, chemical peels, and radiofrequency - as a recovery support tool. This is mechanistically the most direct application of the wound healing evidence: a procedure creates a controlled wound in healthy skin, and PBM supports the cellular repair that follows.
The rationale is well-grounded in the same fibroblast and collagen remodelling biology that underpins the surgical wound evidence. A procedure like CO2 laser resurfacing or deep microneedling creates thousands of micro-injuries across the treatment area. The quality of recovery - how quickly the skin seals, how much redness and swelling follows, and how the collagen remodels underneath - determines both the cosmetic outcome and the downtime. PBM applied in this window supports faster re-epithelialisation, reduces excessive post-procedural inflammation, and supports the organised collagen deposition that determines the final result.
Several dermatology practices now use LED arrays as a standard post-procedure step, applied either immediately after or within the first 24 hours of a treatment. The general clinical recommendation is to apply red and NIR LED at low-to-medium irradiance directly after the procedure, with follow-up sessions every 1-2 days during the acute recovery phase (typically the first 5-7 days), then reducing frequency as the skin heals.
If you have had a skin procedure carried out by a dermatologist or aesthetician, discuss the addition of LED therapy with them before starting - the timing and protocol should align with what has been validated for the specific procedure you have had. As with post-surgical wounds, the window matters: starting in the first 24 hours rather than a week later captures the acute inflammatory and proliferative phases where PBM has the most to offer.
What procedures benefit most
Ablative procedures that remove or disrupt the skin surface - CO2 laser resurfacing, deep microneedling, TCA chemical peels - create the most direct wound-healing context and are where post-procedure PBM is most clinically relevant. Non-ablative treatments that work beneath the surface without breaking it - IPL, non-ablative fractional laser, radiofrequency - also benefit from PBM's anti-inflammatory and circulation effects, but the wound-healing mechanism is less dominant. For all of these, the core principle is the same: PBM supports the repair environment the procedure has initiated.
When to use a panel for different wound types
Timing is the most important practical variable in wound healing applications. The biology of the four phases means there are windows where PBM has more to offer and windows where it has less.
Application timing guide by wound type
This is when the proliferation phase is most active. Daily sessions of 10-20 minutes directly over the incision site. Continue through the first 6-8 weeks for scar prevention. Use both red (630-660nm) and NIR (810-850nm) if available - red acts on surface tissue, NIR reaches deeper layers.
Begin sessions 24-48 hours after injury when the acute bleeding phase has passed. 5-10 minutes at close range (5-10cm). Once or twice daily through the healing period. Earlier application supports a cleaner inflammatory resolution and better collagen organisation.
Cool the burn with water first, apply appropriate dressing. Once the skin surface is intact (not blistered or raw), 660nm red light at low irradiance and moderate distance can support re-epithelialisation. Do not use on deeper burns or infected tissue.
Active scar remodelling continues for up to two years post-injury. For hypertrophic scars, daily sessions over 8-12 weeks are the minimum to see meaningful texture and colour improvement. Older, flat, pale scars have largely finished remodelling and are unlikely to respond significantly.
For diabetic ulcers, pressure ulcers, or any wound that has not progressed in 4 weeks, professional wound care assessment and management should come first. PBM is adjunctive - it supports the healing process but does not replace debridement, infection management, or vascular assessment.
Safety notes
Do not use a panel on open, actively bleeding wounds or on blistered or raw tissue. Do not use on infected wounds without medical guidance - PBM can support healing but does not eradicate bacterial infection. Avoid direct panel use on suspected or known skin malignancies. For deep burns, surgical wounds within the first 24-48 hours, or any wound showing signs of infection (increasing redness, warmth, swelling, discharge), seek medical assessment before using a panel as an adjunct.
Where wound healing fits in the broader picture
Wound healing is not a trending application. It does not generate social media content the way anti-ageing or hair growth does. But it is where red light therapy has the deepest roots and the strongest evidence - and where the mechanism is most direct. You are not trying to produce a cosmetic effect at a distance. You are putting light onto tissue that is actively trying to repair itself, and giving it the cellular energy to do that better.
The skin conditions blog covers wound healing and scarring as two of six conditions in a broader overview. This blog has gone into the detail behind those summaries - the four-phase biology, the TGF-beta and MMP pathways in scar remodelling, the specific clinical protocol parameters from the diabetic ulcer trials, and the post-procedure application that is increasingly standard in dermatology practice.
For anyone who has had surgery, manages a chronic wound, uses a panel after skin procedures, or simply wants to apply it to the cuts and abrasions of daily life: the evidence is there, the timing matters, and earlier is almost always better than later.
Sources
NovaThera
Built on verified science.
630-670nm red and 810-850nm NIR - the wavelengths used in wound healing research. Published irradiance data, no overclaiming.